This site is intended for healthcare professionals
News

FDA Advisory Committee does not support pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.- Acadia Pharma.

Read time: 1 mins
Published:19th Jun 2022

Acadia Pharmaceuticals Inc. announced the outcome of the FDA Psychopharmacologic Drugs Advisory Committee (PDAC) meeting for pimavanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).

The PDAC voted 9 to 3 that the evidence presented does not support a conclusion that pimavanserin is effective for the treatment of hallucinations and delusions in the ADP population.

The FDA asked the PDAC for advice and recommendations regarding the evidence that pimavanserin is effective for the treatment of hallucinations and delusions associated with ADP. The FDA is not bound by the PDAC’s recommendations, but takes its advice into consideration when making decisions on drug applications. The FDA’s target action date is August 4, 2022.

Condition: Alzheimers Disease Psychosis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights